Eligible patients were randomized into two groups: the sodium propionate group and the control group. In the control group, patients received placebo combined with anti-PD-1 therapy plus chemotherapy without additional sodium propionate intervention. In the sodium propionate group, on the basis of anti-PD-1 therapy combined with chemotherapy, patients were additionally administered oral sodium propionate capsules at a dose of 500 mg (1 capsule) twice weekly, with a total intervention duration of 12 weeks. The primary and secondary outcome indicators will be collected for subsequent analysis.
Subjects voluntarily participated in the trial and signed the informed consent form;
Aged ≥ 18 years and < 80 years, regardless of gender;
Stable vital signs;
Patients with gastric adenocarcinoma confirmed by gastroscopic biopsy;
Failure to meet the inclusion criteria, or individuals deemed inappropriate for trial participation by investigators;
Concurrent primary malignant tumors at other sites;
Poor general condition, severe infection, respiratory insufficiency, or other conditions leading to inability to cooperate with the trial;
Patients with mental disorders, consciousness disturbance, or poor treatment compliance;